Powell MA, Roed H, Willmott LJ, Cibula D, et al. Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair
deficient/microsatellite instability-high primary advanced or recurrent
endometrial cancer in the RUBY trial. Gynecol Oncol 2026 May 29:S0090-8258(26)01985.
PMID: 42215378
|